Physician profile

Chloe Cooper

Dallas, TX

NPI 1447839220

$281.32

in general payments reported to CMS, 2019-2025

8 companies · $85.52 in 2025

The $85.52 reported for 2025 was less than what a typical provider received nationally.

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$281.32

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Organon LLC $79.41 2024-2025 Nexplanon
Astellas Pharma US INC $53.77 2023-2024 Veozah
Ethicon US, LLC $34.80 2024 Ethicon
Baxter Healthcare $31.74 2025 Perclot
Evofem Biosciences, INC. $24.60 2024
Sumitomo Pharma America, INC. $23.08 2024
Pfizer INC. $17.63 2025
Amgen INC. $16.29 2025 Evenity

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Chloe Cooper

$281.32

in general payments reported 2019-2025

Years
2023-2025
Top company
Organon LLC
Context
The $85.52 reported for 2025 was less than what a typical provider received nationally.

https://glasscript.com/doctor/11561685/chloe-cooper

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.